BRPI0517374A - formulação para tratamento ou prevenção de infecção respiratória, método para tratamento - Google Patents

formulação para tratamento ou prevenção de infecção respiratória, método para tratamento

Info

Publication number
BRPI0517374A
BRPI0517374A BRPI0517374-4A BRPI0517374A BRPI0517374A BR PI0517374 A BRPI0517374 A BR PI0517374A BR PI0517374 A BRPI0517374 A BR PI0517374A BR PI0517374 A BRPI0517374 A BR PI0517374A
Authority
BR
Brazil
Prior art keywords
formulation
treatment
nanoparticles
vaccine
administered
Prior art date
Application number
BRPI0517374-4A
Other languages
English (en)
Inventor
David A Edwards
Jennifer Fiegel
Jean Sung
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Publication of BRPI0517374A publication Critical patent/BRPI0517374A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Otolaryngology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

FORMULAçãO PARA TRATAMENTO OU PREVENçãO DE INFECçãO RESPIRATóRIA, MéTODO PARA TRATAMENTO. Foram desenvolvidas formulações para tratar ou reduzir a difusão de infecções respiratórias, em especial infecções resistentes à droga ou crónicas, particularmente tuberculose (TB), síndrome respiratória aguda severa (SARS), meningite meningocócica, vírus sincicíal respiratório (RSV), influenza e varíola. As formulações incluem uma droga ou vacina na forma de uma mícroparticula, nanopartícula ou agregado de nanoparticulas e opcíonalmente, um veículo, que podem ser fornecidas por inalação. O fornecimento das drogas através de um inalador evita os problemas associados a drogas oraís ou injetáveis desviando do estómago e fígado, e fornecendo o medicamento diretamente nos pulmões. Em uma modalidade, a partícula contendo o agente é uma partícula de aerossol, porosa, grande (LPPs) . Em outra modalidade, as partículas são nanopartículas, que podem ser administradas como agregados de nanopartícula porosos com diâmetros de mícron que se dispersam em nanopartículas após administração. Opcíonalmente, as nanopartículas são revestidas, como com um revestimento de proteína ou tensoatívo. A formulação pode ser administrada como um pó ou administrada como uma solução ou através de uma via de administração enteral ou parenteral não pulmonar. A formulação é preferivelmente administrada como uma formulação pulmonar. Na modalidade preferida para tratamento de TE, a vacina é uma vacina de BCG que é estável em temperatura ambiente, ou é um antibiótico eficaz contra TE, como capreomicina ou PA-824, carregado em uma percentagem muito elevada nas mícroparticulas ou nanoparticulas. Em uma modalidade, um paciente é tratado com formulações que fornecem tanto antibiótico como vacina.
BRPI0517374-4A 2004-10-29 2005-10-19 formulação para tratamento ou prevenção de infecção respiratória, método para tratamento BRPI0517374A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62373804P 2004-10-29 2004-10-29
PCT/US2005/037484 WO2007011396A2 (en) 2004-10-29 2005-10-19 Particles for treatment of pulmonary infection

Publications (1)

Publication Number Publication Date
BRPI0517374A true BRPI0517374A (pt) 2008-10-07

Family

ID=37667331

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0517374-4A BRPI0517374A (pt) 2004-10-29 2005-10-19 formulação para tratamento ou prevenção de infecção respiratória, método para tratamento

Country Status (11)

Country Link
US (1) US8846607B2 (pt)
EP (1) EP1809252A2 (pt)
JP (1) JP2008518007A (pt)
CN (1) CN101090711A (pt)
AU (1) AU2005334514B2 (pt)
BR (1) BRPI0517374A (pt)
CA (1) CA2585859C (pt)
IL (1) IL182785A0 (pt)
RU (1) RU2007119721A (pt)
WO (1) WO2007011396A2 (pt)
ZA (1) ZA200703452B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11446374B2 (en) 2008-12-09 2022-09-20 Novavax, Inc. Modified RSV F proteins and methods of their use
EP2421518A2 (en) * 2009-04-24 2012-02-29 Schering Corporation Agglomerate formulations including active pharmaceutical agents with targeted particle sizes
CN102458373A (zh) 2009-05-27 2012-05-16 株式会社三养生物制药 生物利用度提高的包含难溶性药物的微球及其制备方法
CN102573886A (zh) * 2009-09-17 2012-07-11 相互制药公司 用抗病毒剂治疗哮喘的方法
CN102225058A (zh) * 2011-06-22 2011-10-26 中国药科大学 磷酸奥司他韦吸入粉雾剂及其制备方法
KR20140147891A (ko) 2012-04-13 2014-12-30 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 응집체 입자
RU2562550C2 (ru) * 2013-12-19 2015-09-10 Федеральное государственное бюджетное научное учреждение "Всероссийский научно-исследовательский институт бруцеллеза и туберкулеза животных" (ФГБНУ ВНИИБТЖ) Способ специфической профилактики туберкулеза
AU2016315478B2 (en) * 2015-09-03 2023-07-13 Novavax, Inc. Vaccine compositions having improved stability and immunogenicity
US20200246268A1 (en) * 2017-06-08 2020-08-06 Pai Life Sciences Inc. Cpzen compositions and uses
CN109260180A (zh) * 2017-07-17 2019-01-25 北京盈科瑞创新药物研究有限公司 一种盐酸莫西沙星雾化吸入用溶液制剂及其制备方法
JP7417532B2 (ja) 2018-03-19 2024-01-18 ノババックス，インコーポレイテッド 多価インフルエンザナノ粒子ワクチン
EA202190331A1 (ru) * 2018-07-24 2021-06-17 Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем Композиции терапевтически активных частиц с модифицированной поверхностью, полученные путем ультрабыстрой заморозки
JPWO2021230340A1 (pt) * 2020-05-14 2021-11-18
JPWO2022044582A1 (pt) * 2020-08-28 2022-03-03
KR20230141782A (ko) * 2021-02-01 2023-10-10 더 글로벌 얼라이언스 포 티비 드러그 디벨롭먼트, 잉크. 프레토마니드 무정형
JP2024049405A (ja) * 2021-02-22 2024-04-10 興和株式会社 新規吸入剤
CN113907360A (zh) * 2021-07-30 2022-01-11 湖南达侑科技有限公司 植物甾醇磷脂组合物及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
US5192528A (en) * 1985-05-22 1993-03-09 Liposome Technology, Inc. Corticosteroid inhalation treatment method
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
IS1796B (is) 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
CA2184242C (en) 1994-02-28 2000-05-02 Jorg Kreuter Drug targeting system, method for preparing same and its use
ATE264096T1 (de) 1994-03-07 2004-04-15 Nektar Therapeutics Verfahren und mittel zur verabreichung von insulin über die lunge
US5814617A (en) 1994-10-07 1998-09-29 The United States Of America As Represented By The Secretary Of The Navy Protective 17 KDA malaria hepatic and erythrocytic stage immunogen and gene
EP0752245B1 (en) 1995-07-05 2002-05-22 European Community Biocompatible and biodegradable nanoparticles designed for proteinaceous drugs absorption and delivery
US6143211A (en) 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
US20020052310A1 (en) 1997-09-15 2002-05-02 Massachusetts Institute Of Technology The Penn State Research Foundation Particles for inhalation having sustained release properties
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6517860B1 (en) * 1996-12-31 2003-02-11 Quadrant Holdings Cambridge, Ltd. Methods and compositions for improved bioavailability of bioactive agents for mucosal delivery
US20030059471A1 (en) * 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US6586008B1 (en) 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
HU229310B1 (en) 1999-10-29 2013-10-28 Nektar Therapeutics Dry powder compositions having improved dispersivity
US6766799B2 (en) 2001-04-16 2004-07-27 Advanced Inhalation Research, Inc. Inhalation device
AU2002364701B8 (en) * 2001-11-20 2006-06-22 Alkermes, Inc. Compositions for sustained action product delivery
GB0216562D0 (en) * 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
AU2003270659A1 (en) * 2002-09-12 2004-04-30 The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services Aerosolized capreomycin for inhibition of pulmonary tuberculosis
CA2500065A1 (en) * 2002-09-30 2004-04-15 Acusphere, Inc. Sustained release porous microparticles for inhalation
DE502004011696D1 (de) * 2003-02-10 2010-11-11 Bayer Schering Pharma Ag Behandlung bakterieller erkrankungen der atmungsorgane durch lokale applikation von fluorchinolonen

Also Published As

Publication number Publication date
WO2007011396A3 (en) 2007-05-03
EP1809252A2 (en) 2007-07-25
CA2585859C (en) 2012-03-06
ZA200703452B (en) 2008-06-25
AU2005334514B2 (en) 2009-11-26
US20080213373A1 (en) 2008-09-04
JP2008518007A (ja) 2008-05-29
CN101090711A (zh) 2007-12-19
CA2585859A1 (en) 2007-01-25
IL182785A0 (en) 2007-09-20
AU2005334514A1 (en) 2007-01-25
WO2007011396A2 (en) 2007-01-25
RU2007119721A (ru) 2008-12-10
US8846607B2 (en) 2014-09-30

Similar Documents

Publication Publication Date Title
BRPI0517374A (pt) formulação para tratamento ou prevenção de infecção respiratória, método para tratamento
Pourshahab et al. Preparation and characterization of spray dried inhalable powders containing chitosan nanoparticles for pulmonary delivery of isoniazid
Kellerman et al. Denufosol: a review of studies with inhaled P2Y2 agonists that led to Phase 3
Zarogoulidis et al. Feasibility and effectiveness of inhaled carboplatin in NSCLC patients
Lehrer Inhaled biguanides and mTOR inhibition for influenza and coronavirus
JP5902628B2 (ja) 相乗的抗ウイルス組成物及びその使用
WO2005084638A3 (en) Formulations decreasing infectivity of pulmonary diseases
BR9908771A (pt) Processos para a liberação de um agente ativo e de insulina para os pulmões de um paciente humano, dispositivo para aumentar a biodisponibilidade de um agente ativo, e, dispositivos para a liberação de um agente ativo e de insulina para os pulmões de um paciente humano
JP2023086774A (ja) 乾燥粉末配合および使用方法
JP2017509684A5 (pt)
JP2008518007A5 (pt)
TNSN06277A1 (en) Pharmaceutical formulations for dry powder inhalers comprising a low-dosage strength active ingredient
WO2010015665A3 (en) Parenteral composition comprising microspheres with a diameter between 10 and 20 microns
AR070835A1 (es) Nueva dosificacion y formulacion de aclidinio para el tratamiento de trastornos respiratorios
BR112014026957A8 (pt) micropartícula, composição compreendendo a mesma, seu uso e sistema de distribuição nasal relacionados ao tratamento de infecções do trato respiratório superior
JP2015515968A5 (pt)
JP2016535094A5 (pt)
WO2013176622A1 (en) A dry powder formulation
Singodia et al. Development and performance evaluation of alginate-capped amphotericin B lipid nanoconstructs against visceral leishmaniasis
WO2015027848A1 (zh) 含有帕拉米韦和/或其衍生物制剂的给药方法
TW200815002A (en) Treating cystic fibrosis with antibiotics via an aerosol drug
TW200815003A (en) Treating cystic fibrosis with antibiotics via a swirler delivery
Rossi et al. Resistant tuberculosis: the latest advancements of second-line antibiotic inhalation products
Hariyadi et al. Performance and drug deposition of kappa-carrageenan microspheres encapsulating ciprofloxacin HCl: Effect of polymer concentration
Debnath et al. Status of inhalable antimicrobial agents for lung infection: progress and prospects

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2256 DE 01/04/2014.